Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

75
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
75
Clinical Trials01:16

Clinical Trials

10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

183
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
183
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

751
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
751
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

124
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
124

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

N=1-studies In Statin-intolerance; Objectifying Nocebo Effects (NISONE): a study protocol for a randomised controlled trial assessing the implementability of N=1-studies to promote the use of statins.

BMJ open·2026
Same author

Variability in anthracycline dose conversions and cardiotoxicity monitoring: insights from hospital pharmacists on institutional protocols in oncology practice.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Digitising controlled substance accountability: implementation and use of a dashboard-based monitoring system in an university hospital.

European journal of hospital pharmacy : science and practice·2026
Same author

Population Pharmacokinetic/Pharmacodynamic Modeling of Therapeutic Enzymes in Lysosomal Storage Diseases.

Clinical pharmacokinetics·2026
Same author

Patient Safety in Anticoagulation: Implementing Safety-II and FRAM in the Medical Curriculum.

Perspectives on medical education·2026
Same author

Response to: Correspondence on 'Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements' by Barzel <i>et al</i>.

European journal of hospital pharmacy : science and practice·2025

Related Experiment Video

Updated: Dec 17, 2025

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.7K

COvid MEdicaTion (COMET) study: protocol for a cohort study.

Roos S G Sablerolles1, Freija E F Hogenhuis2, Melvin Lafeber1

  • 1Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

European Journal of Hospital Pharmacy : Science and Practice
|June 27, 2020
PubMed
Summary

Clinical evidence is needed on how ACE inhibitors and ARBs affect COVID-19 outcomes. This study investigates the relationship between these drugs and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patient results.

Keywords:
adverse effectsclinical pharmacyhypertensionvascular medicinevirology

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.2K

Related Experiment Videos

Last Updated: Dec 17, 2025

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.7K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.2K

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Conflicting theories exist regarding ACE inhibitors and angiotensin II receptor blockers (ARBs) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
  • The mechanism involves angiotensin-converting enzyme 2 (ACE2), which SARS-CoV-2 uses for cell entry.
  • Current evidence is largely based on animal studies, necessitating urgent clinical data.

Purpose of the Study:

  • To investigate the relationship between the use of ACE inhibitors and ARBs and the clinical outcomes of patients with COVID-19.
  • To provide clinical evidence to guide therapeutic strategies and future randomized controlled trials.

Main Methods:

  • A cohort study including patients from multiple European hospitals.
  • Data collection via the Digitalis database, with adjustments for sex, age, cardiovascular disease, hypertension, and diabetes.
  • Analysis of the association between drug use and COVID-19 clinical outcomes.

Main Results:

  • Data collection and analysis are ongoing.
  • Results will clarify the role of ACE inhibitors and ARBs in COVID-19 patient outcomes.
  • Findings will inform clinical decision-making and trial design.

Conclusions:

  • Urgent need for clinical evidence on ACE inhibitors, ARBs, and COVID-19 outcomes.
  • This study aims to provide crucial data for patient management and therapeutic development.
  • Results will facilitate evidence-based choices for preventive and therapeutic strategies against SARS-CoV-2.